Viridian Therapeutics, Inc.\DE (VRDN) Preferred Stock Liabilities (2015 - 2016)
Viridian Therapeutics, Inc.\DE's (VRDN) quarterly Preferred Stock Liabilities came in at $77.0 million in Q4 2016, up 26.5% year-on-year from $60.8 million in Q1 2016, and up 26.5% quarter-over-quarter from $60.8 million in Q4 2015.
Viridian Therapeutics, Inc.\DE (VRDN) Preferred Stock Liabilities (2015 - 2016) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $77.0 million for Q4 2016.
- On a quarterly basis, Preferred Stock Liabilities rose 26.5% year-over-year to $77.0 million in Q4 2016; TTM through Dec 2016 was $77.0 million, a 26.5% increase from a year earlier, with the FY2016 full-year figure at $77.0 million, up 26.5% from the prior year.
- Preferred Stock Liabilities rose to $77.0 million in Q4 2016 per VRDN's latest filing, from $60.8 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $77.0 million in Q4 2016 and bottomed at $60.8 million in Q4 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Viridian Therapeutics, Inc.\DE | 229.55 Mn | 229.55 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 76.98 Mn |
| Dec 31, 2015 | 60.85 Mn |